Comparative Pharmacology
Head-to-head clinical analysis: ALPHAGAN versus CLONIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAGAN versus CLONIDINE.
ALPHAGAN vs CLONIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Selective alpha-2 adrenergic agonist in the brainstem, activating inhibitory neurons, reducing sympathetic outflow, leading to decreased peripheral vascular resistance, renal vascular resistance, heart rate, and blood pressure.
1 drop of 0.1% or 0.15% solution in the affected eye(s) three times daily, approximately 8 hours apart.
Adults: Initial 0.1 mg orally twice daily; maintenance 0.2-0.6 mg/day in divided doses. Transdermal: 0.1-0.3 mg/day patch applied every 7 days. Epidural infusion: 30-40 mcg/hour.
None Documented
None Documented
Clinical Note
moderateClonidine + Digoxin
"Clonidine may increase the atrioventricular blocking (AV block) activities of Digoxin."
Clinical Note
moderateClonidine + Digitoxin
"Clonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin."
Clinical Note
moderateClonidine + Deslanoside
"Clonidine may increase the atrioventricular blocking (AV block) activities of Deslanoside."
Clinical Note
moderateClonidine + Acetyldigitoxin
2.5-3.0 hours in adults; in renal impairment, half-life is prolonged (up to 6 hours).
Terminal elimination half-life: 6-20 hours (mean 12 hours), prolonged in renal impairment (up to 40 hours).
Renal: approximately 70-80% as unchanged drug and metabolites; fecal: 5-10%.
Renal: 40-60% unchanged; hepatic metabolism accounts for ~50%, with metabolites excreted renally. Fecal excretion <5%.
Category C
Category A/B
Alpha-2 Agonist
Alpha-2 Agonist
"Clonidine may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin."